FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172912160> ?p ?o ?g. }

• W2172912160 endingPage "44071" @default.
• W2172912160 startingPage "44061" @default.
• W2172912160 abstract "// Simona Valletta 1 , Hamid Dolatshad 1 , Matthias Bartenstein 2 , Bon Ham Yip 1 , Erica Bello 1 , Shanisha Gordon 2 , Yiting Yu 2 , Jacqueline Shaw 1 , Swagata Roy 1 , Laura Scifo 1 , Anna Schuh 3 , Andrea Pellagatti 1 , Tudor A. Fulga 4 , Amit Verma 2 , Jacqueline Boultwood 1 1 Bloodwise Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford and BRC Blood Theme, NIHR Oxford Biomedical Centre, Oxford University Hospital, Oxford, UK 2 Albert Einstein College of Medicine, Bronx, NY, USA 3 NIHR Biomedical Research Centre, University of Oxford, Oxford, UK 4 Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK Correspondence to: Jacqueline Boultwood, e-mail: jacqueline.boultwood@ndcls.ox.ac.uk Keywords: ASXL1, CRISPR, chronic myeloid leukemia, mutation correction, tumor suppressor Received: July 22, 2015      Accepted: November 08, 2015      Published: November 26, 2015 ABSTRACT Recurrent somatic mutations of the epigenetic modifier and tumor suppressor ASXL1 are common in myeloid malignancies, including chronic myeloid leukemia (CML), and are associated with poor clinical outcome. CRISPR/Cas9 has recently emerged as a powerful and versatile genome editing tool for genome engineering in various species. We have used the CRISPR/Cas9 system to correct the ASXL1 homozygous nonsense mutation present in the CML cell line KBM5, which lacks ASXL1 protein expression. CRISPR/Cas9-mediated ASXL1 homozygous correction resulted in protein re-expression with restored normal function, including down-regulation of Polycomb repressive complex 2 target genes. Significantly reduced cell growth and increased myeloid differentiation were observed in ASXL1 mutation-corrected cells, providing new insights into the role of ASXL1 in human myeloid cell differentiation. Mice xenografted with mutation-corrected KBM5 cells showed significantly longer survival than uncorrected xenografts. These results show that the sole correction of a driver mutation in leukemia cells increases survival in vivo in mice. This study provides proof-of-concept for driver gene mutation correction via CRISPR/Cas9 technology in human leukemia cells and presents a strategy to illuminate the impact of oncogenic mutations on cellular function and survival." @default.
• W2172912160 created "2016-06-24" @default.
• W2172912160 creator A5003135778 @default.
• W2172912160 creator A5007706683 @default.
• W2172912160 creator A5007922486 @default.
• W2172912160 creator A5012667304 @default.
• W2172912160 creator A5037426447 @default.
• W2172912160 creator A5039886481 @default.
• W2172912160 creator A5042478944 @default.
• W2172912160 creator A5046121522 @default.
• W2172912160 creator A5050223014 @default.
• W2172912160 creator A5050749653 @default.
• W2172912160 creator A5060310214 @default.
• W2172912160 creator A5071909219 @default.
• W2172912160 creator A5072901336 @default.
• W2172912160 creator A5074839524 @default.
• W2172912160 creator A5081272972 @default.
• W2172912160 date "2015-11-26" @default.
• W2172912160 modified "2023-10-16" @default.
• W2172912160 title "<i>ASXL1</i> mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts" @default.
• W2172912160 cites W1974343902 @default.
• W2172912160 cites W1974421923 @default.
• W2172912160 cites W1975897697 @default.
• W2172912160 cites W1977709885 @default.
• W2172912160 cites W1986316308 @default.
• W2172912160 cites W1989561383 @default.
• W2172912160 cites W1992320498 @default.
• W2172912160 cites W1999813105 @default.
• W2172912160 cites W1999903619 @default.
• W2172912160 cites W2001858515 @default.
• W2172912160 cites W2003171404 @default.
• W2172912160 cites W2004029643 @default.
• W2172912160 cites W2007818617 @default.
• W2172912160 cites W2014747507 @default.
• W2172912160 cites W2025391163 @default.
• W2172912160 cites W2028030005 @default.
• W2172912160 cites W2028075144 @default.
• W2172912160 cites W2028459384 @default.
• W2172912160 cites W2039045990 @default.
• W2172912160 cites W2045435533 @default.
• W2172912160 cites W2047450548 @default.
• W2172912160 cites W2056833586 @default.
• W2172912160 cites W2058792860 @default.
• W2172912160 cites W2063544405 @default.
• W2172912160 cites W2064815984 @default.
• W2172912160 cites W2076142320 @default.
• W2172912160 cites W2090150670 @default.
• W2172912160 cites W2095340797 @default.
• W2172912160 cites W2096261947 @default.
• W2172912160 cites W2104287429 @default.
• W2172912160 cites W2104654654 @default.
• W2172912160 cites W2108196925 @default.
• W2172912160 cites W2135835093 @default.
• W2172912160 cites W2153424791 @default.
• W2172912160 cites W2170039745 @default.
• W2172912160 cites W2221541771 @default.
• W2172912160 cites W835691338 @default.
• W2172912160 doi "https://doi.org/10.18632/oncotarget.6392" @default.
• W2172912160 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4792541" @default.
• W2172912160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26623729" @default.
• W2172912160 hasPublicationYear "2015" @default.
• W2172912160 type Work @default.
• W2172912160 sameAs 2172912160 @default.
• W2172912160 citedByCount "51" @default.
• W2172912160 countsByYear W21729121602016 @default.
• W2172912160 countsByYear W21729121602017 @default.
• W2172912160 countsByYear W21729121602018 @default.
• W2172912160 countsByYear W21729121602019 @default.
• W2172912160 countsByYear W21729121602020 @default.
• W2172912160 countsByYear W21729121602021 @default.
• W2172912160 countsByYear W21729121602022 @default.
• W2172912160 countsByYear W21729121602023 @default.
• W2172912160 crossrefType "journal-article" @default.
• W2172912160 hasAuthorship W2172912160A5003135778 @default.
• W2172912160 hasAuthorship W2172912160A5007706683 @default.
• W2172912160 hasAuthorship W2172912160A5007922486 @default.
• W2172912160 hasAuthorship W2172912160A5012667304 @default.
• W2172912160 hasAuthorship W2172912160A5037426447 @default.
• W2172912160 hasAuthorship W2172912160A5039886481 @default.
• W2172912160 hasAuthorship W2172912160A5042478944 @default.
• W2172912160 hasAuthorship W2172912160A5046121522 @default.
• W2172912160 hasAuthorship W2172912160A5050223014 @default.
• W2172912160 hasAuthorship W2172912160A5050749653 @default.
• W2172912160 hasAuthorship W2172912160A5060310214 @default.
• W2172912160 hasAuthorship W2172912160A5071909219 @default.
• W2172912160 hasAuthorship W2172912160A5072901336 @default.
• W2172912160 hasAuthorship W2172912160A5074839524 @default.
• W2172912160 hasAuthorship W2172912160A5081272972 @default.
• W2172912160 hasBestOaLocation W21729121601 @default.
• W2172912160 hasConcept C104317684 @default.
• W2172912160 hasConcept C2778461978 @default.
• W2172912160 hasConcept C2778729363 @default.
• W2172912160 hasConcept C41091548 @default.
• W2172912160 hasConcept C501734568 @default.
• W2172912160 hasConcept C502942594 @default.
• W2172912160 hasConcept C54355233 @default.
• W2172912160 hasConcept C71924100 @default.
• W2172912160 hasConcept C75563809 @default.

• next